These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 175676)

  • 1. Volume and time factors in interstitial gamma-ray therapy.
    Barkley HT; Fletcher GH
    AJR Am J Roentgenol; 1976 Jan; 126(1):163-70. PubMed ID: 175676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arrhenius relationships from the molecule and cell to the clinic.
    Dewey WC
    Int J Hyperthermia; 2009 Feb; 25(1):3-20. PubMed ID: 19219695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous beam geometry and intensity map optimization in intensity-modulated radiation therapy.
    Lee EK; Fox T; Crocker I
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):301-20. PubMed ID: 16289912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biological effectiveness of a course of cancer radiation therapy and ways to express it].
    Kholin VV; Frolova ZV
    Med Radiol (Mosk); 1972 Dec; 17(12):64-74. PubMed ID: 4618320
    [No Abstract]   [Full Text] [Related]  

  • 6. [Dose of tissue tolerance, dose of tumour sterilisation in continuous and discontinuous irradiation (author's transl)].
    Swyngedauw J
    J Radiol Electrol Med Nucl; 1975 May; 56(5):369-81. PubMed ID: 1177183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-response relationship for radiation therapy of subclinical disease.
    Withers HR; Peters LJ; Taylor JM
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):353-9. PubMed ID: 7836089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transperineal high-dose-rate interstitial radiation therapy in the management of gynecologic malignancies.
    Itami J; Hara R; Kozuka T; Yamashita H; Nakajima K; Shibata K; Abe Y; Fuse M; Ito M
    Strahlenther Onkol; 2003 Nov; 179(11):737-41. PubMed ID: 14605742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Critical evaluation of the conception of nominal standard dose].
    Kholin VV
    Med Radiol (Mosk); 1976 Jan; 21(1):55-65. PubMed ID: 933736
    [No Abstract]   [Full Text] [Related]  

  • 10. A review of in vitro experimental evidence for the effect of spatial and temporal modulation of radiation dose on response.
    Suchowerska N; Ebert MA; McKenzie DR; Jackson M
    Acta Oncol; 2010 Nov; 49(8):1344-53. PubMed ID: 20553097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of multicellular spheroids in studies based on the NSD (nominal standard dose) concept].
    Ertsgreber G; Shmakova NL; Langrok K
    Radiobiologiia; 1984; 24(2):180-4. PubMed ID: 6729062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Histopathological and histochemical changes in human skin following x-ray therapy in single and fractioned doses].
    Woźniak L; Omulecki A; Studencki E; Pluta J
    Patol Pol; 1972; 23(4):515-23. PubMed ID: 4640605
    [No Abstract]   [Full Text] [Related]  

  • 14. Volume correction factor in time dose relationships in brachytherapy.
    Supe SJ; Sasane JB; Gupta MK
    Strahlenther Onkol; 1987 May; 163(5):309-13. PubMed ID: 3589957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review.
    Tubiana M
    Radiother Oncol; 2009 Apr; 91(1):4-15; discussion 1-3. PubMed ID: 19201045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.
    Suit H; Kooy H; Trofimov A; Farr J; Munzenrider J; DeLaney T; Loeffler J; Clasie B; Safai S; Paganetti H
    Radiother Oncol; 2008 Feb; 86(2):148-53. PubMed ID: 18237800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tritium RBE at low-level exposure--variation with dose, dose rate, and exposure duration.
    Dobson RL; Kwan TC
    Curr Top Radiat Res Q; 1978 Jan; 12(1-4):44-62. PubMed ID: 639559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of tissues to multiple small dose fractions.
    Withers HR
    Radiat Res; 1977 Jul; 71(1):24-33. PubMed ID: 877239
    [No Abstract]   [Full Text] [Related]  

  • 19. Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996-1999): a patterns of care study.
    Erickson B; Eifel P; Moughan J; Rownd J; Iarocci T; Owen J
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1083-92. PubMed ID: 16099599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An effective dose computation model for fractionated radiation dose.
    Akanuma A
    Radiat Med; 1983; 1(2):155-60. PubMed ID: 6679907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.